Autosomal dominant polycystic kidney disease
Therapeutic area
Nephrology
Rare disease
Yes
- Definition
- Autosomal dominant form of polycystic kidney disease.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Autosomal dominant polycystic kidney disease
- Therapeutic area
- Nephrology
- autosomal dominant polycystic kidney disease
- ADPKD
- autosomal dominant polycystic kidney disease
- polycystic kidney disease, autosomal dominant
- All therapeutic areas
- Nephrology
- Severity
- Severe
- Genetic
- Hereditary
- MONDO ID
- MONDO:0004691
- Parent condition
- MONDO:0000426
Related records
Broader conditions (14)
- Autosomal dominant disease
- Autosomal genetic disease
- Cystic kidney disease
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Familial cystic renal disease
- Hereditary disease
- Human disease
- Inherited kidney disorder
- Kidney disorder
- Polycystic kidney disease
- Urinary system disorder
Narrower conditions (7)
- ALG9-associated autosomal dominant polycystic kidney disease
- Polycystic kidney disease 1
- Polycystic kidney disease 2
- Polycystic kidney disease 3 with or without polycystic liver disease
- Polycystic kidney disease 6 with or without polycystic liver disease
- Polycystic kidney disease 7
- Polycystic kidney disease 8
Trials (117)
- 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
- A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
- A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)
- A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
- A Phase 1 Study of Single and Multiple Ascending Doses of GV-100
- A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
- A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province
- A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
- A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
- A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
- A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
- A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults
- A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
- ADPKD Alterations in Hepatic Transporter Function
- ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure?
- ADPKD Cohort Study
- Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
- Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)
Approved drugs (1)
- Tolvaptan
Drugs in development (26)
- Bardoxolone methyl Phase 3
- Bempedoic acid Phase 2
- Bosutinib Phase 2
- Cilnidipine Phase 2
- Empagliflozin Phase 2
- Everolimus Phase 3
- GLPG-2737 Phase 2
- Hydrochlorothiazide Phase 3
- Imidapril Phase 2
- Lanreotide Phase 3
- Lixivaptan Phase 3
- Metformin Phase 3
- Midazolam Phase 1
- Octreotide Phase 3
- Pravastatin Phase 3
- RGLS-4326 Phase 1
- Sirolimus Phase 3
- Sodium chloride Phase 3
- Sodium citrate Phase 2
- Somatostatin Phase 3